A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)

Summary

This study is conducted to evaluate the safety of THR-317 when administered intravitreally and to assess the compound's efficacy in reducing central subfield thickness (CST) and improving best-corrected visual acuity (BCVA) in subjects with macular telangiectasia Type 1 (MacTel 1).

Timeline

Start

2018-09-18

Primary completion

2019-11-22

Completion

2019-11-22

Drugs

Indications